Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportNeurosciences

Increased in vivo binding of [18F]FEMPA to the 18-kDa translocator protein in Alzheimer`s disease

Andrea Varrone
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 137;
Andrea Varrone
1Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

137

Objectives [18F]FEMPA is a novel high-affinity radioligand for the 18-kDa translocator protein (TSPO), displaying suitable pharmacokinetic properties in pre-clinical studies. The aim of this study was to assess whether [18F]FEMPA could detect in vivo increased TSPO binding in Alzheimer`s disease (AD) patients.

Methods Ten AD patients (5M/5F, age 66.9±7.3 y, MMSE 25.5±2.5) and seven controls (3M/4F, age 63.7±7.2 y, MMSE 29.3±1.0) were studied using [18F]FEMPA at Turku (n=13) and at Karolinska Institutet (n=4). The in vitro binding affinity for TSPO was assessed using PBR28 in a competition assay with [3H]PK11195 in 7 controls and 8 AD patients. Cortical and subcortical regions-of-interest were examined. Quantification was performed using Logan graphical analysis. The outcome measure was the total distribution volume (VT). Multivariate analysis was used to assess the effect of group or TSPO binding profile on VT.

Results Five AD and 4 controls were high-affinity binders (HABs). Three AD and 3 controls were mixed-affinity binders. In the medial temporal cortex, a significant difference of VT (p=0.044) was found if the TSPO binding profile was entered as covariate. If only HABs were included, significant differences of VT (p<0.05, Figure) were found in the medial and lateral temporal cortex, caudate, putamen, thalamus, posterior cingulate, and cerebellum.

Conclusions [18F]FEMPA seems to be a suitable radioligand to detect increased TSPO binding in AD if the binding status is taken into account.

Research Support The study was supported by Bayer Healthcare AG. The compound is now part of the portfolio of the Piramal Imaging GmbH, Berlin, Germany.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 54, Issue supplement 2
May 2013
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Increased in vivo binding of [18F]FEMPA to the 18-kDa translocator protein in Alzheimer`s disease
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Increased in vivo binding of [18F]FEMPA to the 18-kDa translocator protein in Alzheimer`s disease
Andrea Varrone
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 137;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Increased in vivo binding of [18F]FEMPA to the 18-kDa translocator protein in Alzheimer`s disease
Andrea Varrone
Journal of Nuclear Medicine May 2013, 54 (supplement 2) 137;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Neurosciences

  • Brain-related complications of COVID-19 and the role of FDG-PET in detecting vascular and non-vascular defects throughout the body
  • A critical review of the utility of PET imaging in the diagnosis and management of psychosis
  • The radiological study of traumatic brain injury: an emphasis upon molecular imaging
Show more Neurosciences

INTEGRATED Session: Inflammation Imaging and Neurological Disease

  • Activated microglia imaging in patients with multiple sclerosis using [11C]PBR28 and high resolution PET: Test-retest reliability
  • Multimodality molecular imaging of translocator protein 18 kDa in a mouse model of Alzheimer’s disease using [18F]PBR06
Show more INTEGRATED Session: Inflammation Imaging and Neurological Disease

Similar Articles

SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire